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Abstract Ceramides play an important role mediating different
cell responses such as proliferation, differentiation, growth arrest
and apoptosis. They are released upon sphingomyelin hydrolysis
which occurs after triggering of a number of cell surface
receptors including CD95. Ceramide generation also regulates
glycosphingolipid and ganglioside metabolism. In particular,
ganglioside GD3 biosynthesis represents an important event for
the progression of apoptotic signals generated by CD95 and
mediated by ceramide in hematopoietic cells.
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1. Introduction
Apoptosis or programmed cell death is a genetically regu-
lated, cellular suicide mechanism that plays a crucial role in
development, homeostasis, and in many diseases including
cancer, AIDS, and autoimmune and degenerative disorders.
The process of apoptosis can be divided into three main
phases: (a) the initiation phase in which, depending on the
stimulus received by the cell, signal transduction and damage
pathways are activated; (b) the e¡ector/decision phase during
which the cell commits itself to die; (c) the degradation phase,
when the cell acquires the morphological and biochemical
hallmarks of apoptosis. Morphologically, cells undergoing
apoptosis show membrane blebbing, nuclear/cytoplasmic con-
densation, fragmentation and packaging of cellular material
into apoptotic bodies. Common biochemical events include
collapse of the mitochondrial inner transmembrane potential,
intracellular acidi¢cation, selective proteolysis of cellular pro-
teins, and degradation of DNA into internucleosomal frag-
ments. It has become clear that mitochondria are major play-
ers during apoptosis and that disruption of the inner
membrane potential which follows the opening of the perme-
ability transition (PT) pore constitutes a decisive event of the
cell death program by apoptosis. This is followed by the re-
lease of di¡usible factors responsible for the activation of
caspases. Thus, any agent capable of inducing mitochondrial
PT is a potential mediator of apoptosis. This appears to be
the case for some lipid and glycolipid e¡ector molecules de-
rived from membrane sphingomyelin metabolism.
2. Ceramide and the sphingomyelinase pathway
Sphingomyelin breakdown initiates an evolutionarily con-
served and ubiquitous intracellular signaling pathway [1^4].
Sphingomyelin is a membrane phospholipid composed of a
sphingosine backbone and fatty acid joined in an amide
bond, and a phosphocholine polar head group. Both sphingo-
sine and the amide-linked fatty acid constitute the lipid com-
ponent of the sphingomyelin moiety called ceramide. As a
major phospholipid, sphingomyelin exists at both the outer
and inner lea£ets of the plasma membranes and is hydrolyzed
by sphingomyelinases, which are sphingomyelin-speci¢c type
C phospholipases, in ceramide and phosphocholine. Di¡erent
pools of sphingomyelin are potentially available to sphingo-
myelinases during membrane biogenesis and degradation.
After being generated in the early Golgi compartments, sphin-
gomyelin is transported along the exocytic pathway to the
extracellular membrane where it is exposed.
Currently, based on their cellular localization and activa-
tion requirements such as pH optimum and cation depend-
ence, ¢ve distinct mammalian sphingomyelinases have been
identi¢ed.
An acidic sphingomyelinase (ASM) found in the lysosomes,
having a pH optimum at about 4.5^5.5, is the product of a
single gene, and requires diacylglycerol (DAG) and zinc to be
activated [5^7]. Genetic mutations of ASM, impairing the
capacity of sphingomyelin degradation, are responsible for
some forms of Niemann-Pick disease (NPD), a group of lethal
diseases characterized by sphingomyelin accumulation in dif-
ferent tissues. ASM activity has been found in every tissue
examined and is localized primarily in caveolae, endosomes
and lysosomes [8].
Additionally, a Zn2-dependent ASM has also been found
in serum [9]. It is secreted by diverse cell types and is a prod-
uct of the ASM gene that occurs independently of alternative
splicing.
A neutral membrane-bound Mg2-dependent sphingomye-
linase (NSM), produced by a di¡erent gene [10], has been
described in several mammalian tissues. It shows a neutral
(7^7.5) pH optimum and is activated by arachidonic acid
[11]. Another neutral Mg2-independent NSM has been char-
acterized. This phospholipase is present in the cytosol and is
activated by 1,25-dihydroxyvitamin D3 [12]. The last enzyme
has an alkaline pH optimum and was found in the gastro-
intestinal tract [13].
3. Sphingomyelin breakdown in signal transduction
Sphingomyelin breakdown represents the most relevant
source of ceramide involved in signal transduction. Di¡erent
stimuli have been shown to induce sphingomyelin degradation
and ceramide generation. Among these are vitamin D3 [6],
dexamethasone [14], ionizing radiation [15], as well as ligation
of di¡erent membrane receptors, such as the tumor necrosis
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factor receptor-1 [16,17], CD95 [18], CD40 [19], the nerve
growth factor receptor [20], CD28 [21] and the interleukin-1
receptor [22]. Moreover, sphingomyelin hydrolysis is associ-
ated with the cellular response to stresses such as nutrient
withdrawal and radiations [15,23].
Ceramide has been shown to activate multiple pathways. A
sequential activation of di¡erent kinases, initiated by a ceram-
ide-activated protein kinase (CAPK), involves phosphoryla-
tion of Raf-1, and subsequently of the mitogen-activated pro-
tein kinase cascade [24]. Importantly, ceramide has been
proved to act as a catalyst for the stress response kinase cas-
cade through the consecutive involvement of MEKK1, SEK1,
SAPK and c-Jun [25]. A ceramide-induced PKCj phosphoryl-
ation may contribute to NF-UB translocation [26]. Finally,
along with protein kinase activation, ceramide has been
shown to activate a heterotrimeric protein phosphatase of
the PP2A family [27], which might be responsible for ceram-
ide-induced downregulation of c-myc and cell cycle arrest
[28].
4. Early apoptotic signaling through the CD95 receptor
CD95 is a widely distributed surface receptor whose cross-
linking by its speci¢c ligand triggers apoptosis. Crosslinking
of CD95 results in the activation of two main pathways in-
volved in the early propagation of apoptotic signals, both
requiring integrity of the receptor death domain: a proteolytic
cascade mediated by caspases and the activation of the lipid
pathway including the activation of the acidic sphingomyelin-
ase.
Upon ligand-induced receptor oligomerization, the adaptor
molecule FADD/MORT1 binds directly to CD95 via its
death domain. Concomitantly, the ‘e¡ector domain’ of
FADD/MORT1 interacts with a homologous domain of
caspase-8 (FLICE/MACH) resulting in the activation not
only of caspase-8 itself but of the downstream caspase cascade
[29,30].
The activation of sphingomyelin turnover has been sug-
gested to play an important role in initiating the biochemical
pathway leading to active cell death, since the synthetic cer-
amide analogue C2-ceramide has been shown to be directly
responsible for apoptosis induction in di¡erent cell lines. In
human cutaneous T cell lymphoma HuT78 cells, an early
ceramide accumulation mediated by both neutral (NSM)
and acidic (ASM) sphingomyelinases occurs transiently within
the ¢rst 30 min after CD95 crosslinking [18,31]. Analysis of
Fas-resistant cellular mutants revealed that only ceramide re-
leased by ASM is relevant for apoptosis [31]. Moreover, cells
from individuals a¡ected with NPD, genetically de¢cient in
ASM activity, or from mice in which the gene encoding
ASM has been targeted, show remarkable defects in executing
the apoptotic program in response to radiations [32]. Accord-
ingly, in NPD lymphoblasts, in which CD95 signaling is im-
paired, an e⁄cient CD95-mediated apoptotic program can be
reconstituted by direct replacement of ASM [33]. These data
strongly support the involvement of ASM in generating cer-
amide as a mediator of apoptotic cell death.
A later and prolonged ceramide accumulation, dependent
on cytosolic NSM activation, occurs several hours after CD95
crosslinking. This increase in ceramide intracellular concentra-
tion is prolonged and persistent and is also important for the
later progression of apoptotic signals [34].
5. The mitochondrial route to caspases
The induction of mitochondrial PT is a critical event in
apoptosis [35,36]. This event is due to the opening of a dy-
namic multiprotein complex, the mitochondrial megachannel,
also called the PT pore. It causes the dissipation of the inner
mitochondrial transmembrane potential Q (vim) leading to an
expansion of the cellular matrix, organellar swelling, and dis-
ruption of the outer membrane. This latter event thereby per-
mits the release of apoptogenic factors, including cytochrome
c and apoptosis-inducing factor (AIF), and intramitochon-
drial caspases such as caspase-9 and -2. AIF can induce nu-
clear apoptosis. Cytochrome c, once in the cytosol, in associ-
ation with dATP, binds to the CED-4 homologue, Apaf-1,
triggering caspase-9. Upon activation of caspase-9, a cascade
of caspase activation events is initiated [37]. Caspase-9 recruits
caspase-3 which, in turn, triggers CAD, a caspase-activated
DNase responsible for DNA fragmentation. Bcl-2 prevents,
via a direct e¡ect on mitochondrial membranes, all hallmarks
of the early stage of apoptosis including disruption of the
inner mitochondrial transmembrane potential and the release
of apoptogenic factors such as cytochrome c, AIF, and casp-
ase-2 and -9.
As mitochondrial damage is a crucial step of apoptosis, it
became obvious to ask whether ceramide could disrupt the
mitochondrial membrane potential. According to several au-
thors, ceramide induces PT when added to the cell but there is
controversy about the capacity of ceramide to induce PT in
isolated mitochondria. Some reports say ceramide can [38],
others that it cannot [36]. Another group found that cytosols
Fig. 1. General scheme for ganglioside biosynthesis. Cer, ceramide;
GluCer, glucosylceramide; LacCer, lactosylceramide; Glu, glucose;
Gal, galactose; Sia, sialic acid; GalNac, N-acetylgalactosamine;
GM, monosialogangliosides; GD, disialogangliosides; GT, trisialo-
gangliosides.
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from ceramide-treated cells could induce PT on isolated mi-
tochondria from untreated control cells. However, the addi-
tion of ceramide to cytosols does not generate PT [39]. Taken
together, these latter data suggest that in intact cells, ceramide
triggers the generation of another second messenger able to
disrupt the mitochondrial membrane potential.
6. Ceramide as a source of disialoganglioside GD3
Newly synthesized or released ceramides are targeted to the
Golgi apparatus and regulate sphingolipid and glycosphingo-
lipid metabolism, including the rate of ganglioside biosynthe-
sis within the Golgi [40,41].
Gangliosides are amphipathic constituents of the outer leaf-
let of cellular membranes, composed of a common hydropho-
bic ceramide moiety, which acts as a membrane anchor, and a
hydrophilic oligosaccharide chain. Ganglioside neosynthesis is
initiated within the biogenic membranes of the early Golgi by
stepwise glycosylation of ceramide. New-formed ceramides
coming from the endoplasmic reticulum, or free ceramides
coming from degradative subcellular compartments, enter
the early Golgi via vesicular membrane £ow to initiate gan-
glioside synthesis. The addition of glucose by the action of a
cytosolic glucosyltransferase turns ceramide into glucosylcer-
amide (Fig. 1). Subsequently, a cytosolic galactosyltransferase
mediates the attachment of a galactose residue to the glucose,
forming lactosylceramide. Lactosylceramide then £ips into the
luminal side of early Golgi cisternae, where the attachment of
a sialic acid residue over the galactose, mediated by K-2,3-
sialyltransferase, generates GM3, the ¢rst sialylated ganglio-
side. GM3 may give rise to either the monosialylated ganglio-
side series (GM2, GM1, etc.), or to GD3, GT3, GQ3, etc., by
the sequential addition of more sialic acid residues.
In CD95-mediated apoptosis, we demonstrated that ceram-
ide synthesis induces the accumulation of the disialoganglio-
side GD3 [42]. GD3 results from the addition of a second
sialic acid to the one present on GM3, mediated by the action
of GD3 synthase (K-2,8-sialyltransferase), a transmembrane
type II protein of about 40 kDa resident in the early Golgi.
GD3 transiently accumulates after apoptotic stimulation via
CD95 in HuT78 and U937 tumor cells, but not in cell variants
which are resistant to CD95 crosslinking. C2-ceramide, but
not C2-dihydroceramide which is ine¡ective in inducing apop-
tosis, is su⁄cient to induce GD3 accumulation. CD95-induced
GD3 accumulation is prevented by speci¢c GD3 synthase
antisense oligonucleotides. Moreover, NPD lymphoblasts
have an impaired CD95-mediated apoptosis and cannot accu-
mulate ganglioside GD3 whereas ASM-reconstituted NPD
lymphoblasts can accumulate GD3 and undergo e⁄cient
CD95-mediated apoptosis. Therefore, ASM is required for
GD3 ganglioside accumulation in response to CD95 [33]
and triggering the apoptotic program accelerates GD3 syn-
thase function and GD3 neosynthesis. Similarly to ceramides,
GD3 can e⁄ciently induce cell death in both HuT78 and
U937 cells, while other gangliosides such as GD1a, GT1b or
GM1 do not, when added exogenously. Interestingly, CD95-
resistant HuT78 and U937 cell lines, which failed to accumu-
late GD3 after CD95 crosslinking, are as sensitive as their
respective wild type cell lines to GD3, suggesting that exoge-
nous GD3 restores the ability to trigger the apoptotic pro-
gram in cells with upstream signaling defects which result in
lack of GD3 accumulation. Furthermore, the transient over-
expression of the GD3 synthase induces apoptosis in HuT78
cells. CD95-induced cell death is substantially prevented using
antisense oligonucleotides which block GD3 synthase expres-
sion. Thus, the ganglioside GD3 mediates cell death induced
by CD95 crosslinking and ceramide.
Inhibitors of caspases, involved in CD95-induced apoptosis,
prevent GD3 accumulation upon CD95 crosslinking indicat-
ing that upstream caspase activation is required for GD3 ac-
cumulation and that one or more caspases control GD3 syn-
thesis. Attempts to identify potential targets in the GD3
apoptotic pathway revealed that v8m disruption is a rapid
event that precedes all the major apoptotic features induced
by GD3 when added to the cells. Moreover, our preliminary
results indicate that GD3 accumulates in close proximity to
mitochondria of cells undergoing apoptosis, and that GD3,
but not other gangliosides such as GD1a, GM1 or GM3, can
directly induce PT on isolated mitochondria, with consequent
release of the apoptogenic factors cytochrome c and AIF.
These data corroborate the hypothesis that ceramide acts on
mitochondria after conversion to GD3. Thus, mitochondria
may represent the site where GD3 meets its targets (Fig. 2).
7. Conclusions and perspectives
The acidic sphingomyelinase-mediated pathway therefore
Fig. 2. Schematic representation of CD95-induced signaling. ASM,
acidic sphingomyelinase; PC-PLC, phosphatidylcholine-speci¢c
phospholipase C; CytC, cytochrome c ; casp, caspase; Cer, ceram-
ide; AIF, apoptosis-inducing factor; ST8, K-2,8-sialyltransferase.
FEBS 22004 2-6-99 Cyaan Magenta Geel Zwart
F. Malisan, R. Testi/FEBS Letters 452 (1999) 100^103102
contributes to apoptotic signals originating from CD95 death
domains. The analysis of genetic models of ASM de¢ciency in
humans and targeted disruption of the ASM gene in mice has
established the role of ASM in the progression of apoptotic
signals. The involvement of GD3 in the apoptotic program is
consistent with the notion that only ceramides produced by
ASM in the endocytic degradative compartments come into
close functional and topological proximity to the membrano-
genic organelles, and engage the biosynthetic pathways. In
keeping with the notion of the importance of signal compart-
mentalization, GD3 synthase mutants, lacking the transmem-
brane domain and therefore not addressed to the Golgi, can-
not induce apoptosis of transfected cells as the wild type
enzyme does (our unpublished observation). Thus, one of
the roles of ASM-released ceramide in apoptosis would be
to serve as a precursor of ganglioside GD3, also indicating
the early Golgi, where GD3 is generated by GD3 synthase, as
a critical subcellular compartment for the progression of
apoptotic signals. Some of the neosynthesized GD3 could
then be targeted to the mitochondria. Thus, this lipid messen-
ger participates in the optimal completion of the apoptotic
process in hematopoietic cells by recruiting mitochondria to
the program. Additional studies are needed to identify GD3
targets on mitochondria.
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